Treatment options and long-term outcomes of horses with subchondral lucencies of the medial femoral condyle

Subchondral lucencies (SCL) occur in the equine medial femoral condyle (MFC) and can cause lameness and impair performance. Treatment of MFC SCL has evolved over the last 40 years from rest alone to cyst injection to several surgical procedures. Horses most commonly develop MFC SCL in the first 18 months of life, and expectations for performance and sales can impact therapeutic decisions. These complications mean that a single treatment plan cannot be applied to every SCL. An additional issue is accurate long-term performance data. Long-term follow-up can also be difficult to obtain due to horse movement, confidentiality issues after sales, and the complexities of finding new owners and getting their cooperation. This short communication reviews available racing information from publications reporting treatment of MFC SCL and provides long-term follow-up racing data on 13 horses treated with a transcondylar screw. Horses receiving a transcondylar screw raced as well as horses treated with other procedures and had longer careers, further supporting the use of this technique in the treatment of MFC SCL.